In this article
French biotech Abivax has told CNBC that it denied a French media report that AstraZeneca was in talks to acquire it.
The report by La Lettre said that AstraZeneca had had exclusive access to Abivax’s data since early February and had until March 23 to formalize an offer. The publication cited “our sources.”
The Abivax spokesperson told CNBC that they denied the report in its entirety but didn’t comment further on the specific points in the article. AstraZeneca earlier declined to comment.
Abivax has been the subject of intense takeover speculation for months, and its stock price has soared as a result.
